bay-k-8644 has been researched along with Chronic Disease in 5 studies
3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester: A dihydropyridine derivative, which, in contrast to NIFEDIPINE, functions as a calcium channel agonist. The compound facilitates Ca2+ influx through partially activated voltage-dependent Ca2+ channels, thereby causing vasoconstrictor and positive inotropic effects. It is used primarily as a research tool.
Bay-K-8644 : A racemate comprising equimolar amounts of (R)- and (S)-Bay-K-8644
methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate : A pentasubstituted dihydropyridine carrying methoxycarbonyl, 2-(trifluoromethyl)phenyl and nitro substituents at positions 3, 4 and 5 respectively as well as two methyl substituents at positions 2 and 6.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wan, J | 1 |
| Yamamura, A | 1 |
| Zimnicka, AM | 1 |
| Voiriot, G | 1 |
| Smith, KA | 1 |
| Tang, H | 1 |
| Ayon, RJ | 1 |
| Choudhury, MS | 1 |
| Ko, EA | 1 |
| Wang, J | 1 |
| Wang, C | 1 |
| Makino, A | 1 |
| Yuan, JX | 1 |
| Savignac, M | 1 |
| Gomes, B | 1 |
| Gallard, A | 1 |
| Narbonnet, S | 1 |
| Moreau, M | 1 |
| Leclerc, C | 1 |
| Paulet, P | 1 |
| Mariamé, B | 1 |
| Druet, P | 1 |
| Saoudi, A | 1 |
| Fournié, GJ | 1 |
| Guéry, JC | 1 |
| Pelletier, L | 1 |
| Peers, C | 2 |
| Carpenter, E | 2 |
| Hatton, CJ | 2 |
| Wyatt, CN | 2 |
| Bee, D | 2 |
| Schotten, U | 1 |
| Ausma, J | 1 |
| Stellbrink, C | 1 |
| Sabatschus, I | 1 |
| Vogel, M | 1 |
| Frechen, D | 1 |
| Schoendube, F | 1 |
| Hanrath, P | 1 |
| Allessie, MA | 1 |
5 other studies available for bay-k-8644 and Chronic Disease
| Article | Year |
|---|---|
Chronic hypoxia selectively enhances L- and T-type voltage-dependent Ca2+ channel activity in pulmonary artery by upregulating Cav1.2 and Cav3.2.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; 3-Pyridinecarboxylic acid, 1,4-d | 2013 |
Dihydropyridine receptors are selective markers of Th2 cells and can be targeted to prevent Th2-dependent immunopathological disorders.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 2004 |
Ca2+ channel currents in type I carotid body cells of normoxic and chronically hypoxic neonatal rats.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1996 |
Ca2+ channel currents in type I carotid body cells from normoxic and chronically hypoxic rats.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1996 |
Cellular mechanisms of depressed atrial contractility in patients with chronic atrial fibrillation.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 2001 |